Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics’ SEC disclosures don’t just list numbers—they unpack gene-therapy science, TRACER™ capsid breakthroughs, and clinical trial risks that shape the company’s future. Yet finding R&D burn rates, partnership milestone payments, or CNS efficacy data inside a 200-page 10-K can feel daunting.
Stock Titan solves that problem. Our AI reads every Voyager Therapeutics annual report 10-K simplified, each Voyager Therapeutics quarterly earnings report 10-Q filing, and even those time-sensitive 8-K material events explained, surfacing what matters most: trial updates, cash runway changes, and FDA feedback. Interactive summaries translate dense biotech language into plain English so you spend minutes—not hours—understanding Voyager Therapeutics SEC filings explained simply.
Need to monitor management moves? Receive Voyager Therapeutics Form 4 insider transactions real-time, including executive stock transactions Form 4, so you can spot buying or selling before crucial data releases. Follow compensation shifts through the Voyager Therapeutics proxy statement executive compensation section, and track funding trends with our Voyager Therapeutics earnings report filing analysis.
Because filings post without warning, we deliver real-time alerts the moment EDGAR releases a document. Investors use these insights to:
- Compare quarter-over-quarter R&D spend against cash reserves
- Verify milestone revenue from licensing deals
- Gauge regulatory momentum via 8-K event updates
- Cross-reference Voyager Therapeutics insider trading Form 4 transactions with trial timelines
Whether you’re understanding Voyager Therapeutics SEC documents with AI or tracking Voyager Therapeutics 8-K material events explained, our platform brings every disclosure into focus so you can make informed decisions on this pioneering CNS gene-therapy company.
Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc. (VYGR), reported the sale of 19,000 shares of the issuer's common stock on 08/18/2025 at a weighted average price of $3.73 per share. After the reported sale, Mr. Ferguson beneficially owned 138,914 shares, held directly. The filing discloses that the $3.73 figure is a weighted average for multiple transactions executed at prices ranging from $3.69 to $3.79 and states the reporting person will provide a detailed breakdown of shares sold at each price on request. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Voyager Therapeutics, Inc. (VYGR) filed a Form 144 notifying a proposed sale of 19,000 common shares that vested as restricted stock on 04/01/2025. The shares are held at Fidelity Brokerage Services and were acquired as compensation. The filer estimates an aggregate market value of $70,680 and reports 55,468,806 shares outstanding; the approximate sale date is 08/18/2025 on NASDAQ. The filer reports no sales in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 4,800,000 shares of Voyager Therapeutics, Inc. common stock, representing 8.65% of the outstanding shares based on 55,468,806 shares outstanding. The filing states Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and that Armistice exercises shared voting and dispositive power over the reported shares. Neither Armistice nor Mr. Boyd claim sole voting or dispositive power. The Master Fund is identified as the holder with the right to receive proceeds or dividends.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
